NASDAQ:ACRS Aclaris Therapeutics (ACRS) Stock Price, News & Analysis → Elon Musk’s Controversial New Project: “Apollo” (From InvestorPlace) (Ad) Free ACRS Stock Alerts $1.22 0.00 (0.00%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$1.22▼$1.2550-Day Range$1.15▼$1.4452-Week Range$0.59▼$11.12Volume636,944 shsAverage Volume1.51 million shsMarket Capitalization$86.53 millionP/E RatioN/ADividend YieldN/APrice Target$22.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Aclaris Therapeutics alerts: Email Address Aclaris Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.14 Rating ScoreUpside/Downside1,723.8% Upside$22.25 Price TargetShort InterestHealthy6.89% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.98) to ($0.87) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.48 out of 5 starsMedical Sector676th out of 909 stocksPharmaceutical Preparations Industry311th out of 422 stocks 3.1 Analyst's Opinion Consensus RatingAclaris Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 1 buy rating, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageAclaris Therapeutics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.89% of the outstanding shares of Aclaris Therapeutics have been sold short.Short Interest Ratio / Days to CoverAclaris Therapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aclaris Therapeutics has recently decreased by 4.49%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAclaris Therapeutics does not currently pay a dividend.Dividend GrowthAclaris Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACRS. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Aclaris Therapeutics this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added Aclaris Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aclaris Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.50% of the stock of Aclaris Therapeutics is held by insiders.Percentage Held by Institutions98.34% of the stock of Aclaris Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Aclaris Therapeutics are expected to grow in the coming year, from ($0.98) to ($0.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aclaris Therapeutics is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aclaris Therapeutics is -0.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAclaris Therapeutics has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceElon Musk’s Controversial New Project: “Apollo”Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...Click here to see the details because there's a lot of money at stake. About Aclaris Therapeutics Stock (NASDAQ:ACRS)Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.Read More ACRS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ACRS Stock News HeadlinesApril 11, 2024 | finance.yahoo.comFavourable Signals For Aclaris Therapeutics: Numerous Insiders Acquired StockMarch 16, 2024 | finance.yahoo.comACRS Apr 2024 1.000 callApril 24, 2024 | InvestorPlace (Ad)Elon Musk’s Controversial New Project: “Apollo”Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...March 4, 2024 | markets.businessinsider.comAclaris Therapeutics: Cautious Hold Rating Amid Financial Stability and Pipeline PotentialMarch 1, 2024 | markets.businessinsider.comAclaris Therapeutics: Hold Rating Amidst Strategic Review and Clinical SetbacksFebruary 29, 2024 | finance.yahoo.comAnalysts Have Just Cut Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Revenue Estimates By 51%February 27, 2024 | msn.comAclaris Therapeutics GAAP EPS of -$0.02 beats by $0.31, revenue of $17.6M beats by $12.55MFebruary 27, 2024 | globenewswire.comAclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate UpdateApril 24, 2024 | InvestorPlace (Ad)Elon Musk’s Controversial New Project: “Apollo”Have you seen this footage outside the headquarters of Elon Musk's "Project Apollo?" Big Tech and the mainstream media have called this project "controversial"...February 20, 2024 | finance.yahoo.comPacira (PCRX) Earnings Expected to Grow: What to Know Ahead of Q4 ReleaseFebruary 15, 2024 | finance.yahoo.comWill Aclaris Therapeutics (ACRS) Report Negative Q4 Earnings? What You Should KnowFebruary 6, 2024 | msn.comAclaris Therapeutics Executive Team Undergoes Major ChangesJanuary 22, 2024 | msn.comHW Wainwright cuts Aclaris to neutral, cites underwhelming study dataJanuary 16, 2024 | msn.comWhy Is Dermatology Focused Aclaris Therapeutics Stock Trading Higher Today?January 16, 2024 | bizjournals.comAclaris moves on from CEO and begins strategic review following recent setbacksJanuary 11, 2024 | msn.comBTIG Downgrades Aclaris Therapeutics (ACRS)January 11, 2024 | markets.businessinsider.comThe Analyst Landscape: 4 Takes On Aclaris TherapeuticsJanuary 11, 2024 | realmoney.thestreet.comJefferies gets more bearish on Aclaris Therapeutics, downgrades sharesJanuary 10, 2024 | msn.comAclaris downgraded at Jefferies despite mid-stage win for eczema therapyJanuary 10, 2024 | markets.businessinsider.comAnalyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data VariationsJanuary 10, 2024 | msn.comAclaris Therapeutics Shares Fall On Mixed Results From Mid-Stage Eczema TrialJanuary 10, 2024 | marketwatch.comAclaris Therapeutics Shares Down 12% Following Top-Line Results for Atopic Dermatitis TreatmentJanuary 10, 2024 | markets.businessinsider.comAclaris Therapeutics Reports Positive Top-line Results From Phase 2b ATI-1777-AD-202 StudyJanuary 10, 2024 | finance.yahoo.comAclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic DermatitisJanuary 4, 2024 | msn.comAre Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?January 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX), Aclaris Therapeutics (ACRS) and Ocular Therapeutix (OCUL)December 30, 2023 | markets.businessinsider.comBuy Rating Justified by Aclaris Therapeutics’ Strategic Focus and Robust Financial ManagementSee More Headlines Receive ACRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today4/23/2024Next Earnings (Estimated)5/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ACRS CUSIPN/A CIK1557746 Webwww.aclaristx.com Phone(484) 324-7933Fax484-320-2344Employees86Year Founded2012Price Target and Rating Average Stock Price Target$22.25 High Stock Price Target$38.00 Low Stock Price Target$9.00 Potential Upside/Downside+1,723.8%Consensus RatingHold Rating Score (0-4)2.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-88,480,000.00 Net Margins-283.15% Pretax Margin-284.32% Return on Equity-64.56% Return on Assets-49.10% Debt Debt-to-Equity RatioN/A Current Ratio4.16 Quick Ratio4.16 Sales & Book Value Annual Sales$31.25 million Price / Sales2.77 Cash FlowN/A Price / Cash FlowN/A Book Value$2.22 per share Price / Book0.55Miscellaneous Outstanding Shares70,930,000Free Float67,024,000Market Cap$86.53 million OptionableOptionable Beta0.22 Social Links These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesDr. Neal S. Walker D.O. (Age 54)M.D., Co-Founder, President, Chairman & Interim CEO Comp: $955.69kDr. Joseph Monahan Ph.D. (Age 67)Chief Scientific Officer Comp: $600.02kMr. Kevin Balthaser (Age 36)Chief Financial Officer Mr. Matthew Rothman J.D.General Counsel & Corporate SecretaryDr. Jon Jacobsen Ph.D.Senior Vice President of ChemistryMr. James Loerop (Age 59)Chief Business Officer More ExecutivesKey CompetitorsAssertioNASDAQ:ASRTReviva PharmaceuticalsNASDAQ:RVPHEton PharmaceuticalsNASDAQ:ETONBeyondSpringNASDAQ:BYSIQ32 BioNASDAQ:QTTBView All CompetitorsInsiders & InstitutionsBML Capital Management LLCBought 8,742,827 shares on 4/23/2024Ownership: 13.247%Perceptive Advisors LLCSold 500,000 shares on 2/26/2024Ownership: 0.000%Octagon Capital Advisors LPBought 100,000 shares on 2/15/2024Ownership: 0.141%Bain Capital Life Sciences Investors LLCBought 100,000 shares on 2/13/2024Ownership: 4.944%Affinity Asset Advisors LLCSold 260,000 shares on 2/13/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions ACRS Stock Analysis - Frequently Asked Questions Should I buy or sell Aclaris Therapeutics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ACRS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACRS, but not buy additional shares or sell existing shares. View ACRS analyst ratings or view top-rated stocks. What is Aclaris Therapeutics' stock price target for 2024? 7 analysts have issued 12 month price targets for Aclaris Therapeutics' stock. Their ACRS share price targets range from $9.00 to $38.00. On average, they predict the company's stock price to reach $22.25 in the next twelve months. This suggests a possible upside of 1,723.8% from the stock's current price. View analysts price targets for ACRS or view top-rated stocks among Wall Street analysts. How have ACRS shares performed in 2024? Aclaris Therapeutics' stock was trading at $1.05 at the beginning of 2024. Since then, ACRS shares have increased by 16.2% and is now trading at $1.22. View the best growth stocks for 2024 here. When is Aclaris Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our ACRS earnings forecast. How were Aclaris Therapeutics' earnings last quarter? Aclaris Therapeutics, Inc. (NASDAQ:ACRS) issued its quarterly earnings results on Tuesday, February, 27th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.07. The biotechnology company earned $17.57 million during the quarter, compared to analyst estimates of $3.96 million. Aclaris Therapeutics had a negative trailing twelve-month return on equity of 64.56% and a negative net margin of 283.15%. What is Neal Walker's approval rating as Aclaris Therapeutics' CEO? 1 employees have rated Aclaris Therapeutics Chief Executive Officer Neal Walker on Glassdoor.com. Neal Walker has an approval rating of 100% among the company's employees. This puts Neal Walker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Aclaris Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aclaris Therapeutics investors own include TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Trevena (TRVN), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP), OPKO Health (OPK), Abeona Therapeutics (ABEO) and Aldeyra Therapeutics (ALDX). Who are Aclaris Therapeutics' major shareholders? Aclaris Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BML Capital Management LLC (13.25%). Insiders that own company stock include Andrew N Schiff, David N Gordon, Douglas J Manion, Frank Ruffo, James Loerop, Joseph Monahan, Kamil Ali-Jackson, Kevin Balthaser and Neal Walker. View institutional ownership trends. How do I buy shares of Aclaris Therapeutics? Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ACRS) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarThe A.I. story nobody is telling you (Read ASAP)TradeSmithtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencySHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
